Clinical Trials on Non-Small Cell Lung Cancer NSCLC

Total 8012 results

H. Lee Moffitt Cancer Center and Research Institute
Nestlé Health Science

Withdrawn

Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢA

United States
Stanford University
The American Association of Physicists in Medicine

Terminated

Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors

Pancreatic Cancer | Lung Cancer | Liver Cancer | Hepatobiliary Cancers | Hepatobiliary Cancers Liver | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC) | Hepatobiliary Cancers Hepatocellular Carcinoma (Hepatoma) | Hepatobiliary Cancers Gallbladder | Hepatobiliary Cancers...

United States
Genentech, Inc.
Flatiron Health, Inc.; Foundation Medicine, Inc.

Completed

Prospective Clinicogenomic Program (PCG)

Non-Small Cell Lung Cancer (NSCLC) | Small-Cell Lung Cancer (SCLC)

United States
Stanford University

Terminated

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Lung Cancer | Mesothelioma | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC)

United States
Jun Zhang, MD, PhD
Genentech, Inc.; Exelixis

Not yet recruiting

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) (Cabatezo-1)

Lung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung Cancer

United States
Mythic Therapeutics

Recruiting

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung Cancer

United States, Australia, Korea, Republic of, United Kingdom, Spain
Elephas
Beaufort CRO

Recruiting

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-01)

NSCLC | Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

NSCLC | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Non-small Cell Carcinoma

United States
University of Alabama at Birmingham
Sanofi

Completed

Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC) | Metastatic NSCLC | Stage IV NSCLC

United States
Joel Neal
Nektar Therapeutics

Completed

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Tumors Metastatic to Brain | Stage IV Non-small Cell Lung Cancer (NSCLC) | Recurrent Non-small Cell Lung Cancer (NSCLC) | Extensive-stage Small Cell Lung Cancer (SCLC) | Recurrent Small Cell Lung Cancer (SCLC) | Metastatic Breast Cancer (mBC)

United States
Heather Wakelee
Novartis; Genentech, Inc.

Terminated

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC), Recurrent | Non-small Cell Lung Cancer (NSCLC), Stage IV

United States
Oslo University Hospital
AstraZeneca

Active, not recruiting

Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study (DART)

Cancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage III

Norway, Finland, Lithuania, Estonia
Clovis Oncology, Inc.

Terminated

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Small Cell Lung Cancer | Non-Small Cell Lung Cancer | NSCLC | Lung Cancer | Metastatic Lung Cancer | SCLC | Stage IV Lung Cancer | Advanced Lung Cancer | Squamous Non-Small Cell Lung Cancer

United States, Italy, Germany, France, Spain
Radiotherapy Oncology Centre "Santa Maria" Hospital
Paola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MD

Recruiting

Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer (STARTNEWERA-OM)

NSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditions

Italy
Amgen
Parexel

Withdrawn

A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Metastatic Non-small Cell Lung Cancer (NSCLC) | Non-squamous NSCLC
WindMIL Therapeutics
Bristol-Myers Squibb

Terminated

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

NSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Metastatic

United States
Bristol-Myers Squibb

Completed

Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer

Lung Cancer | Non-small Cell Lung Cancer NSCLC | Small Cell Lung Cancer SCLC

China
National Cancer Centre, Singapore
Pfizer

Active, not recruiting

Phase 2 Study of Dacomitinib in NSCLC

NSCLC Stage IV | NSCLC Stage IIIB | Recurrent NSCLC | NSCLC Stage IIIC | EGFR Positive Non-Small Cell Lung Cancer

Korea, Republic of, Hong Kong, Thailand, Singapore, Malaysia
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer | NSCLC, Stage III | Nsclc | NSCLC Stage II

United States
Rain Oncology Inc

Terminated

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients (TH-4000)

NSCLC | Non-small Cell Lung Cancer | Non-squamous NSCLC

United States, Australia
Washington University School of Medicine
Merck Sharp & Dohme LLC

Withdrawn

Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small Cell Lung Extensive Stage
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Minimal Residual Disease | NSCLC Stage IV | Nsclc | Metastatic Non Small Cell Lung Cancer

United States
Pfizer

Completed

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC

United States, Canada, Australia, Taiwan, Singapore, Japan, Korea, Republic of, Spain, Belgium, Switzerland, France, Germany, Hong Kong, Italy
AIO-Studien-gGmbH
Bristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaborators

Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (CRISP)

Small-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage II

Germany
Groupe Français de Pneumo-Cancérologie

Completed

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) (EGFR-RETRO)

NSCLC Non Small Cells Lung Cancer

France
Washington University School of Medicine
Eli Lilly and Company; ImmunityBio, Inc.

Withdrawn

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Carcinoma
Memorial Sloan Kettering Cancer Center
AstraZeneca

Recruiting

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

NSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

United States
Washington University School of Medicine
Eli Lilly and Company

Completed

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer

United States
Maastricht Radiation Oncology
University Medical Center Groningen; The Netherlands Cancer Institute

Completed

Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC (NVALT11)

Non Small Cell Lung Cancer (NSCLC) | Stage III Non-Small Cell Lung Cancer | Radical Treatment

Netherlands
Kyowa Kirin Korea Co., Ltd.

Terminated

Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma | Phase 2 Portion : Small Cell Lung Cancer(SCLC)

Korea, Republic of
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL797 in Adults With Solid Tumors

Advanced Breast Cancer | NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Recurrent Breast Cancer | TNBC - Triple-Negative Breast Cancer | Relapsed Cancer | NSCLC, Recurrent | Recurrent... and other conditions

United States
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Non-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

United States
Maximilian Diehn
AstraZeneca

Recruiting

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Non Small Cell Lung Cancer | NSCLC, Stage III | Nsclc

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | TNBC - Triple-Negative Breast Cancer | NSCLC Stage IV Without EGFR/ALK Mutation

United States, Canada
Marc de Perrot
Ozmosis Research Inc.

Not yet recruiting

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection (SUPER)

Non-small Cell Lung Cancer (NSCLC) | Lung Cancer Patients
Bristol-Myers Squibb

Not yet recruiting

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Non-small Cell Lung Cancer (NSCLC)

United Kingdom
Merck Sharp & Dohme LLC

Not yet recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NSCLC | Non-small Cell Lung Cancer
Sun Yat-sen University

Not yet recruiting

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

China
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (OSTARA)

Non-Small Cell Lung Cancer (NSCLC)

Korea, Republic of, Malaysia, Taiwan, Thailand, Hong Kong, Singapore, Canada
Duke University
Regeneron Pharmaceuticals

Recruiting

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Non-small Cell Lung Cancer (NSCLC)

United States
Shanghai Chest Hospital

Recruiting

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Non-Small Cell Lung Cancer (NSCLC)

China
AstraZeneca

Completed

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

Unresectable Non-small Cell Lung Cancer (NSCLC)

India
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Switzerland, Australia
AstraZeneca

Active, not recruiting

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)

Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, Belgium, Poland, Taiwan, Thailand, Korea, Republic of, Russian Federation, Austria
BeiGene

Terminated

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

China, Australia
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Sweden, Swit... and more
State University of New York - Upstate Medical...

Completed

Outcome of Patients With Lung Masses Who Are Treated With Radiofrequency Ablation (RFA)

Non-small Cell Lung Cancer (NSCLC)

United States
AstraZeneca

Completed

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United Kingdom, United States, Italy, Spain, Germany, France
Bristol-Myers Squibb

Completed

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen (CheckMate153)

Non Small Cell Lung Cancer (NSCLC)

United States, Canada

Clinical Trials on Non-Small Cell Lung Cancer NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations